Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Medicure (MCUJF) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Medicure (MCUJF) over the last 17 years, with Q3 2025 value amounting to $19.4 million.

  • Medicure's Liabilities and Shareholders Equity fell 706.93% to $19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.9 million, marking a year-over-year decrease of 180.58%. This contributed to the annual value of $21.2 million for FY2024, which is 308.27% up from last year.
  • Latest data reveals that Medicure reported Liabilities and Shareholders Equity of $19.4 million as of Q3 2025, which was down 706.93% from $20.5 million recorded in Q2 2025.
  • In the past 5 years, Medicure's Liabilities and Shareholders Equity registered a high of $25.2 million during Q2 2021, and its lowest value of $19.4 million during Q3 2025.
  • For the 5-year period, Medicure's Liabilities and Shareholders Equity averaged around $22.0 million, with its median value being $21.6 million (2023).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first crashed by 2239.83% in 2021, then surged by 308.27% in 2024.
  • Quarter analysis of 5 years shows Medicure's Liabilities and Shareholders Equity stood at $22.5 million in 2021, then dropped by 2.27% to $22.0 million in 2022, then dropped by 6.43% to $20.6 million in 2023, then rose by 3.08% to $21.2 million in 2024, then dropped by 8.63% to $19.4 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $19.4 million for Q3 2025, versus $20.5 million for Q2 2025 and $20.8 million for Q1 2025.